HK1187605A1 - 作為 調節劑的吡唑氨基嘧啶衍生物 - Google Patents

作為 調節劑的吡唑氨基嘧啶衍生物

Info

Publication number
HK1187605A1
HK1187605A1 HK14100468.7A HK14100468A HK1187605A1 HK 1187605 A1 HK1187605 A1 HK 1187605A1 HK 14100468 A HK14100468 A HK 14100468A HK 1187605 A1 HK1187605 A1 HK 1187605A1
Authority
HK
Hong Kong
Prior art keywords
lrrk2
modulators
aminopyrimidine derivatives
pyrazole
pyrazole aminopyrimidine
Prior art date
Application number
HK14100468.7A
Other languages
English (en)
Inventor
查爾斯．貝克-格倫
丹尼爾．喬恩．伯狄克
馬克．錢伯斯
陳慧芬
安東尼．埃斯特拉德
扎卡里．凱文．斯威尼
布萊恩．
．尚
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1187605A1 publication Critical patent/HK1187605A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK14100468.7A 2010-11-10 2014-01-16 作為 調節劑的吡唑氨基嘧啶衍生物 HK1187605A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41227310P 2010-11-10 2010-11-10
US201161546613P 2011-10-13 2011-10-13
PCT/EP2011/069696 WO2012062783A1 (en) 2010-11-10 2011-11-09 Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Publications (1)

Publication Number Publication Date
HK1187605A1 true HK1187605A1 (zh) 2014-04-11

Family

ID=44983512

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14100468.7A HK1187605A1 (zh) 2010-11-10 2014-01-16 作為 調節劑的吡唑氨基嘧啶衍生物

Country Status (28)

Country Link
US (1) US8815882B2 (zh)
EP (3) EP2638031B9 (zh)
JP (3) JP5986094B2 (zh)
KR (1) KR101566091B1 (zh)
CN (1) CN103313978B (zh)
AR (1) AR083813A1 (zh)
AU (1) AU2011328139A1 (zh)
BR (1) BR112013011600B1 (zh)
CA (2) CA3017869C (zh)
CY (1) CY1120073T1 (zh)
DK (2) DK3124483T3 (zh)
EC (1) ECSP13012611A (zh)
ES (2) ES2746134T3 (zh)
HK (1) HK1187605A1 (zh)
HR (2) HRP20172006T1 (zh)
HU (2) HUE037844T2 (zh)
IL (1) IL225234A0 (zh)
LT (2) LT3124483T (zh)
MA (1) MA34644B1 (zh)
MX (1) MX2013005199A (zh)
NO (1) NO2638031T3 (zh)
PL (2) PL3124483T3 (zh)
PT (2) PT3124483T (zh)
RS (2) RS56583B1 (zh)
SG (1) SG189043A1 (zh)
SI (2) SI2638031T1 (zh)
TW (1) TW201302733A (zh)
WO (1) WO2012062783A1 (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013030095A2 (pt) 2011-05-23 2019-09-24 Elan Pharm Inc inibidores de atividade de lrrk2 cinase
US20140228384A1 (en) * 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
EP2785711B1 (en) * 2011-11-29 2016-08-03 F.Hoffmann-La Roche Ag 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
RU2634716C2 (ru) 2011-11-29 2017-11-03 Дженентек, Инк. Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
CN106349234A (zh) * 2011-11-29 2017-01-25 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
WO2013079496A1 (en) * 2011-11-30 2013-06-06 F. Hoffmann-La Roche Ag Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2
CA2870049C (en) * 2012-05-03 2020-12-29 Charles Baker-Glenn Pyrazole aminopyrimidine derivatives as lrrk2 modulators
MX358172B (es) * 2012-05-03 2018-08-08 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
NZ721726A (en) 2013-12-17 2021-07-30 Merck Patent Gmbh N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
CN106170290A (zh) 2013-12-20 2016-11-30 西格诺药品有限公司 取代的二氨基嘧啶基化合物、其组合物及其治疗方法
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds
EA029774B1 (ru) * 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
WO2015148867A1 (en) * 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US9859504B2 (en) * 2014-03-31 2018-01-02 Commonwealth Scientific And Industrial Research Organisation Diamine compounds for phosphorescent diazaborole metal complexes and electroluminescent devices
JP6637880B2 (ja) * 2014-05-08 2020-01-29 東ソー・ファインケム株式会社 ５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
US10058559B2 (en) 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 ４−（２，２，２−トリフルオロエトキシ）−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 ５−（トリフルオロメチル）ピリミジン誘導体及びその製造法
US10059689B2 (en) 2014-10-14 2018-08-28 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
MX2018003215A (es) 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
EP3436443B1 (en) 2016-03-29 2020-03-11 Merck Patent GmbH N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
US10428024B2 (en) 2016-04-28 2019-10-01 Merck Patent Gmbh Piperidinyl derivatives
PL3472153T3 (pl) 2016-06-16 2022-02-07 Denali Therapeutics Inc. Pirymidyn-2-yloamino-1h-pirazole jako inhibitory lrrk2 do zastosowania w leczeniu zaburzeń neurodegeneracyjnych
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
EP3586848B1 (en) 2017-02-24 2021-09-01 Daegu-Gyeongbuk Medical Innovation Foundation Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
US20200157081A1 (en) * 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
LT3645518T (lt) * 2017-06-30 2021-10-11 Amgen Inc. Omekamitivo mekarbilo sintezė
TW201920197A (zh) * 2017-07-14 2019-06-01 英商葛蘭素史克智慧財產發展有限公司 化合物
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
MX2020005332A (es) 2017-11-21 2021-01-08 Denali Therapeutics Inc Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion.
AU2018392599A1 (en) 2017-12-20 2020-07-09 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
JP7364841B2 (ja) * 2018-02-14 2023-10-19 智彦 大和田 酸ハロゲン化物による化合物の製造方法
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
EA202193285A1 (ru) * 2019-05-31 2022-03-04 Денали Терапьютикс Инк. Состав с модифицированным высвобождением соединения пиримидиниламинопиразола и способы лечения
CN110627810B (zh) * 2019-06-05 2024-05-10 中国医学科学院药用植物研究所 一种三氟甲基吡唑衍生物的制备方法
CA3170252A1 (en) * 2020-03-06 2021-09-10 Chun-Ping Chang Pyrimidine compounds and their pharmaceutical uses
KR102342803B1 (ko) 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
CN115413278A (zh) 2020-03-23 2022-11-29 丸仁制药株式会社 新型嘧啶衍生物以及包含其的神经退行性疾病和癌症的预防或治疗用组合物
EP4232040A1 (en) 2020-10-20 2023-08-30 F. Hoffmann-La Roche AG Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
EP4308115A1 (en) * 2021-03-17 2024-01-24 Merck Sharp & Dohme LLC Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CA3213359A1 (en) * 2021-03-26 2022-09-29 Bettina FRANZ Alk-5 inhibitors and uses thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023174946A1 (en) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Early and non-invasive method for assessing a subject's risk of having parkinson's disease
WO2023224894A1 (en) * 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2024097394A1 (en) 2022-11-03 2024-05-10 Denali Therapeutics Inc. Solid and co-crystal forms of a pyrimidine triazole compound
WO2024112746A1 (en) 2022-11-22 2024-05-30 Denali Therapeutics Inc. Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692484B2 (en) 1993-10-12 1998-06-11 Du Pont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
KR100643419B1 (ko) 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
US6172222B1 (en) 1998-06-08 2001-01-09 American Home Products Corporation Diaminopyrazoles
US6458823B1 (en) 1998-06-08 2002-10-01 Wyeth Diaminopyrazoles
HU230394B1 (hu) 1998-11-10 2016-04-28 Janssen Pharmaceutica N.V. HIV-vírus szaporodását gátló pirimidin-származékok
MXPA02001565A (es) 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
BRPI0014271B1 (pt) 1999-09-24 2021-06-22 Janssen Pharmaceutica N.V. Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
EP1282606B1 (en) 2000-05-08 2015-04-22 Janssen Pharmaceutica NV Hiv replication inhibiting pyrimidines and triazines
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290914A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002046184A1 (en) 2000-12-05 2002-06-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
SI1343782T1 (sl) 2000-12-21 2009-10-31 Smithkline Beecham Corp Pirimidinamini kot modulatorji angiogeneze
CN102250071A (zh) 2000-12-21 2011-11-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
EP1404669A2 (en) 2001-05-16 2004-04-07 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
PL367130A1 (en) 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
AU2002315388A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
US20030139435A1 (en) 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
DK1438053T3 (da) 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
WO2003055489A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
JP2005526765A (ja) * 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
CN1717396A (zh) 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
WO2004067516A1 (en) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
WO2004103975A1 (de) 2003-05-21 2004-12-02 Bayer Cropscience Aktiengesellschaft Iodpyrazolylcarboxanilide
US20060229308A1 (en) 2003-07-15 2006-10-12 Neurogen Corporation Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands
KR20120062863A (ko) * 2003-07-30 2012-06-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물
CA2533870A1 (en) 2003-07-30 2005-02-10 Shudong Wang Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
JP4741491B2 (ja) 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1786783A1 (en) 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
KR20070091018A (ko) 2004-12-17 2007-09-06 아스트라제네카 아베 Ｃｄｋ 억제제로서의4-(4-(이미다졸-4-일)피리미딘-2-일아미노)벤즈아미드
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
DE102005008310A1 (de) 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
EP1705177A1 (en) 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
EP1888561A1 (en) * 2005-05-05 2008-02-20 AstraZeneca AB Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US7589197B2 (en) 2005-06-14 2009-09-15 Taigen Biotechnology Pyrimidine compounds
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
CA2621057A1 (en) 2005-09-07 2007-03-15 Laboratoires Serono S.A. Ikk inhibitors for the treatment of endometriosis
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
PE20080068A1 (es) 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2032543A1 (en) 2006-06-15 2009-03-11 Boehringer Ingelheim International GmbH 2-anilino-4-aminoalkyleneaminopyrimidines
US20080131937A1 (en) 2006-06-22 2008-06-05 Applera Corporation Conversion of Target Specific Amplification to Universal Sequencing
WO2008016675A1 (en) 2006-08-01 2008-02-07 Praecis Pharmaceuticals Incorporated P38 kinase inhibitors
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
US20080194575A1 (en) 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
AU2007324850A1 (en) 2006-11-27 2008-06-05 Ares Trading S.A. Treatment for multiple myeloma
EP2091918B1 (en) 2006-12-08 2014-08-27 Irm Llc Compounds and compositions as protein kinase inhibitors
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
CA2670645A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
CA2673184A1 (en) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh New compounds
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
CN101679376A (zh) 2007-06-08 2010-03-24 拜尔农科股份有限公司 杀真菌剂杂环-嘧啶基-氨基衍生物
KR20100049068A (ko) 2007-07-17 2010-05-11 리겔 파마슈티칼스, 인크. Ｐｋｃ 억제제로서의 시클릭 아민 치환된 피리미딘디아민
ES2457394T3 (es) 2007-09-28 2014-04-25 Cyclacel Limited Derivados de pirimidina como inhibidores de proteína cinasa
US8058279B2 (en) 2007-10-09 2011-11-15 Dow Agrosciences Llc Insecticidal pyrimidinyl aryl hyrdrazones
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009071535A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
US8367687B2 (en) 2007-12-07 2013-02-05 Novartis Ag Pyrazole derivatives
SI2265607T1 (sl) 2008-02-15 2017-06-30 Rigel Pharmaceuticals, Inc. Spojine pirimidin-2-amina in njihova uporaba kot inhibitorji JAK kinaz
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
NO2300013T3 (zh) 2008-05-21 2018-02-03
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
CA2729227C (en) 2008-06-25 2018-05-22 Andrew W. Hinman 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
UA101676C2 (uk) 2008-07-31 2013-04-25 Дженентек, Инк. Піримідинові сполуки, композиції і способи застосування
US20110159019A1 (en) 2008-09-01 2011-06-30 Akira Tanaka 2,4-diaminopyrimidine compound
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
CN102203080A (zh) 2008-09-03 2011-09-28 拜尔农作物科学股份公司 作为杀菌剂的杂环取代的苯胺基嘧啶
JP2012501981A (ja) 2008-09-03 2012-01-26 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのヘテロ環置換アニリノピリミジン類
KR20110049905A (ko) 2008-09-03 2011-05-12 바이엘 크롭사이언스 아게 4-알킬-치환된 디아미노피리미딘
WO2010028179A1 (en) 2008-09-03 2010-03-11 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds as gata modulators
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP5908728B2 (ja) 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
US20110071158A1 (en) 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
AU2010231694A1 (en) * 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
US20120040955A1 (en) 2009-04-14 2012-02-16 Richard John Harrison Fluoro substituted pyrimidine compounds as jak3 inhibitors
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2010144468A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
US20120142667A1 (en) 2009-06-10 2012-06-07 Nigel Ramsden Pyrimidine derivatives as zap-70 inhibitors
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
US20120172384A1 (en) 2009-06-18 2012-07-05 Mihiro Sunose Heterocyclylaminopyrimidines as kinase inhibitors
WO2010146132A1 (en) 2009-06-18 2010-12-23 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
AU2010295690B2 (en) 2009-09-16 2016-07-28 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
EA021437B1 (ru) 2009-09-29 2015-06-30 Глэксо Груп Лимитед Соединения, ингибирующие lrrk2 киназную активность
CA2780892C (en) 2009-11-13 2017-02-14 Genosco Kinase inhibitors
KR20120125611A (ko) 2009-12-29 2012-11-16 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 이종이량체 결합 단백질 및 이의 용도
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
KR101531448B1 (ko) * 2010-06-04 2015-06-24 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서의 아미노피리미딘 유도체
CN106349234A (zh) * 2011-11-29 2017-01-25 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
RU2634716C2 (ru) * 2011-11-29 2017-11-03 Дженентек, Инк. Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
EP2785711B1 (en) * 2011-11-29 2016-08-03 F.Hoffmann-La Roche Ag 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
WO2013079496A1 (en) * 2011-11-30 2013-06-06 F. Hoffmann-La Roche Ag Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2

Also Published As

Publication number Publication date
EP3124483A1 (en) 2017-02-01
CA2812669C (en) 2018-11-06
EP3124483B1 (en) 2019-07-10
PL3124483T3 (pl) 2020-03-31
CA3017869A1 (en) 2012-05-18
TW201302733A (zh) 2013-01-16
EP3590933B1 (en) 2021-01-06
PL2638031T3 (pl) 2018-03-30
ES2746134T3 (es) 2020-03-04
DK2638031T3 (en) 2017-12-11
EP2638031B9 (en) 2020-01-08
BR112013011600B1 (pt) 2022-01-11
HUE046617T2 (hu) 2020-03-30
DK3124483T3 (da) 2019-09-02
RS59106B1 (sr) 2019-09-30
RS56583B1 (sr) 2018-02-28
AU2011328139A1 (en) 2013-04-04
LT2638031T (lt) 2017-12-11
LT3124483T (lt) 2019-09-25
JP5986094B2 (ja) 2016-09-06
KR101566091B1 (ko) 2015-11-04
US20120157427A1 (en) 2012-06-21
HUE037844T2 (hu) 2018-09-28
CY1120073T1 (el) 2018-12-12
JP6524284B2 (ja) 2019-06-05
EP2638031A1 (en) 2013-09-18
SG189043A1 (en) 2013-05-31
SI2638031T1 (en) 2018-02-28
CA3017869C (en) 2021-07-27
HRP20191781T1 (hr) 2019-12-27
CA2812669A1 (en) 2012-05-18
AR083813A1 (es) 2013-03-27
EP3590933A1 (en) 2020-01-08
PT3124483T (pt) 2019-10-02
BR112013011600A2 (pt) 2016-08-09
CN103313978A (zh) 2013-09-18
MX2013005199A (es) 2013-06-28
JP2018109038A (ja) 2018-07-12
IL225234A0 (en) 2013-06-27
JP6298115B2 (ja) 2018-03-20
EP2638031B1 (en) 2017-10-11
ECSP13012611A (es) 2013-07-31
BR112013011600A8 (pt) 2021-09-08
MA34644B1 (fr) 2013-11-02
HRP20172006T1 (hr) 2018-02-09
ES2653967T3 (es) 2018-02-09
NO2638031T3 (zh) 2018-03-10
JP2017008074A (ja) 2017-01-12
CN103313978B (zh) 2015-04-15
KR20130093657A (ko) 2013-08-22
PT2638031T (pt) 2018-01-03
SI3124483T1 (sl) 2019-10-30
JP2013545741A (ja) 2013-12-26
WO2012062783A1 (en) 2012-05-18
US8815882B2 (en) 2014-08-26

Similar Documents

Publication Publication Date Title
HRP20160771T1 (hr) Derivati aminopirimidina kao modulatori za lrrk2
HK1187605A1 (zh) 作為 調節劑的吡唑氨基嘧啶衍生物
HK1200820A1 (zh) 作為 調節劑的吡唑氨基嘧啶衍生物
HK1210778A1 (zh) 嘧啶吡唑基衍生物
AP2948A (en) Thienopyrmidinedione derivatives as TRPA1 modulators
HK1166081A1 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
HK1200819A1 (zh) 作為 調節劑用於治療帕金森病的吡唑氨基嘧啶衍生物
ZA201304282B (en) Pyrazole derivative
ZA201209029B (en) Novel pyrimidine derivatives
HK1191862A1 (zh) 吡唑衍生物
HK1201836A1 (zh) 新型吡咯衍生物
EP2542075A4 (en) Fluorouracil DERIVATIVES
GB201106796D0 (en) Pyrrole derivatives